Showing results (151-160 of 274) with videos related to
Sort By:
Pageof 28
Cancer|January 22, 2010
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancerGisele A Sarosy, Mahrukh M Hussain, Michael V Seiden, et al.JCO Precision Oncology|February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid TumorsYiduo Hu, Azeet Narayan, Yunshan Xu, et al.Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.Cancer Letters|November 3, 2010
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanismChiara Corrado, Stefania Raimondo, Anna Maria Flugy, et al.British Journal of Clinical Pharmacology|March 12, 2011
Population pharmacokinetic analysis of sorafenib in patients with solid tumoursLokesh Jain, Sukyung Woo, Erin R Gardner, et al.Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Christina M Annunziata, Amanda J Walker, Lori Minasian, et al.Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.Gynecologic Oncology|November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaAndrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.Journal of the National Cancer Institute|March 15, 2014
Better therapeutic trials in ovarian cancerMichael A Bookman, C Blake Gilks, Elise C Kohn, et al.Pageof 28